Skip links

SSOT-powered AI Unleashes a New Era for Digital Practitioners

Jump To Section

In the dynamic realm of artificial intelligence, the ascent of Single Source of Truth (SSOT) emerges as a paradigm shift, reshaping the landscape for digital practitioners. Within this transformative wave, the integration of SSOT with cutting-edge Generative AI not only streamlines operations but ushers in a new age of efficiency and innovation, especially when it comes to self-service features for business users.

Elevating Self-Service with Generative AI and SSOT

Traditionally shackled by the dependence on tech teams for every nuanced data query, business users now wield unprecedented autonomy through SSOT-powered self-service features. The synergy with Generative AI, particularly through Natural Language Query (NLQ) capabilities, exemplifies this liberation.

Consider a scenario where a business user, sans technical jargon, can articulate complex queries in plain language. Thanks to SSOT, acting as the bastion of data integrity, coupled with Generative AI’s NLQ prowess, instant and intelligible responses become the norm. This isn’t just a leap in accessibility; it’s a strategic maneuver in making data-driven decisions an intuitive process.

Here are a few examples: 

Question #1 asked by business user on data stored in DB: How many ownership_customers from 'Pharma Business Unit' were active in MI?
 
SQL generated by GenAI model:
 
SELECT COUNT(DISTINCT customer.id) AS ownership_customers_count
 
FROM customer
 
JOIN transaction ON customer.id = transaction.customer_id
 
JOIN product ON transaction.product_id = product.id
 
WHERE product.business_unit = 'Pharma Business Unit'
   
AND transaction.shipping_address_state = 'MI';

GenAI solution’s response: 132 customers

Question #2 asked by business user on data stored in DB: What is the total sales in Texas?
 
SQL generated by GenAI model:
 
SELECT SUM(sales_amount) AS total_sales
 
FROM transaction
 
WHERE shipping_address_state = 'TX';
 


GenAI solution’s response: 253467.00 dollar

Rapid AI Model Development: The SSOT Advantage

The perennial bottleneck in AI model development – grappling with data cleaning, integrity, and disparate sources – is fundamentally altered by SSOT. It serves as the bedrock, obviating the need for perpetual data wrangling. This pivotal shift allows machine learning engineers to redirect their focus from the trenches of data management to the frontiers of AI model training.

With SSOT in the equation, the development cycle accelerates exponentially. The newfound freedom to explore intricate algorithms and experiment with avant-garde approach becomes the norm. The result? A reinvigorated landscape where AI development isn’t stifled by data intricacies but propelled by SSOT’s efficiency.

Future Trajectory: Where SSOT and AI Converge

Looking forward, the trajectory for digital practitioners teems with possibilities. SSOT’s ascendancy is not just a temporal victory; it sets the stage for a future where the amalgamation of SSOT with emerging technologies amplifies the technical arsenal.

Imagine an AI infrastructure where SSOT seamlessly integrates with advanced natural language processing and sophisticated analytics. The crux is democratizing insights, thrusting business users into the forefront of decision-making with unprecedented technical prowess.

In conclusion, the rise of SSOT-powered AI is a watershed moment for digital practitioners. This isn’t just about data integrity; it’s about sculpting a future where businesses wield data as a potent asset. As SSOT and AI converge, the digital landscape stands on the precipice of unprecedented innovation, and those who harness this amalgamation will redefine what’s possible in the digital realm.

Premjeet Kumar

Premjeet Kumar

Latest Reads

Subscribe

Suggested Reading

Ready to Unlock Yours Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes